<DOC>
	<DOCNO>NCT02134990</DOCNO>
	<brief_summary>The study prospective open-label single-center study previously treat patient Non Small Cell Lung Cancer ( NSCLC ) . Treatment efficacy safety combination Oshadi D Oshadi R Docetaxel evaluate . Patients receive Docetaxel combination Oshadi D Oshadi R. Patient evaluate throughout study safety tolerance multiple dose regimen Oshadi D Oshadi R. CT MRI imaging perform prior treatment initiation end every 3 Docetaxel cycle ( 12 week ) . In case disease progression , dose augmentation consider subsequent therapy .</brief_summary>
	<brief_title>Oshadi D Oshadi R Combination With Docetaxel , 2nd Line Therapy Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Locally advanced metastatic NSCLC ( IIIBIV ) Failure first line anticancer therapy ( either radiological documentation disease progression due toxicity ) advance disease subsequent relapse disease follow first line therapy Man woman 21 year Adequate performance status ( ECOG 0 , 1 ) Patient must adequate organ function Written inform consent Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 6 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Any treatment investigational agent within 10 day prior registration protocol therapy . Cerebrovascular accident , transient ischemic attack myocardial infarction within 3 month prior registration protocol therapy . Evidence pulmonary embolism within 3 month prior registration protocol therapy . Any history hematologic malignancy . Patient known positive HIV serology screen . Female patient breastfeed positive pregnancy test screening time study . Uncontrolled hypertension ( &gt; 160/100 mm Hg despite optimal medical therapy ) . Evidence ongoing cardiac dysrhythmias NCI CTCAE ( Common Toxicity Criteria Adverse Effects ) Version 3.0 grade 2 . Patients radiation surgery indicate Significant swallow disorder . Small bowel surgery . Suspicion absorption disruption result abdominal radiation Preexisting mal absorption syndrome , irritable bowel syndrome clinical situation could affect oral absorption . Evidence concurrent ( &lt; 5 year ) second malignancy Mental disorder . Inability give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Docetaxel</keyword>
</DOC>